Дэвид Перлмуттер - Промывка мозга. Программа для ясного мышления, укрепления отношений с людьми и развития полезных привычек

C-реактивный белок не является маркером депрессии. На основании его уровня невозможно ни заподозрить депрессию, ни подтвердить диагноз, ни подобрать терапию, ни сменить ее. Прим. науч. ред.

M. K. Wium-Andersen et al. “C-Reactive Protein Levels, Psychological Distress, and Depression in 73, 131 Individuals,” JAMA Psychiatry 70, № 2 (2013): 176–184.

V. Valkanova, K. P. Ebmeier, and C. L. Allan. “CRP, IL-6 and Depression: A Systematic Review and Meta-Analysis of Longitudinal Studies,” J. Affect. Disord. 150, № 3 (September 2013): 736–744.

A. N. Westover and L. B. Marangell. “A Cross-National Relationship Between Sugar Consumption and Major Depression?” Depress. Anxiety 16, № 3 (2002): 118–120.

A. Sanchez-Villegas et al. “Added Sugars and Sugar-Sweetened Beverage Consumption, Dietary Carbohydrate Index and Depression Risk in the Seguimiento Universidad de Navarra (SUN) Project,” Br. J. Nutr. 119, № 2 (January 2018): 211–221.

J. E. Gangwisch et al. “High Glycemic Index Diet as a Risk Factor for Depression: Analyses from the Women’s Health Initiative,” Am. J. Clin. Nutr. 102, № 2 (August 2015): 454–463.

C. Lassale et al. “Healthy Dietary Indices and Risk of Depressive Outcomes: A Systematic Review and Meta-Analysis of Observational Studies,” Mol. Psychiatry 24, № 7 (July 2019): 965–986.

Glenda Lindseth, Brian Helland, and Julie Caspers. “The Effects of Dietary Tryptophan on Affective Disorders,” Archives of Psychiatric Nursing 29, № 2 (April 2015): 102–107.

G. Z. Réus et al. “Kynurenine Pathway Dysfunction in the Pathophysiology and Treatment of Depression: Evidences from Animal and Human Studies,” J. Psychiatr. Res. 68 (September 2015): 316–328.

Réus et al. “Kynurenine Pathway Dysfunction.”

J. Savitz. “Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorder,” Current Topics in Behavioral Neuroscience 31 (2017): 249–267.

T. B. Meier et al. “Relationship between Neurotoxic Kynurenine Metabolites and Reductions in Right Medial Prefrontal Cortical Thickness in Major Depressive Disorder,” Brain Behav. Immun. 53 (March 2016): 39–48.

Y. Zhou et al. “Cross-Sectional Relationship between Kynurenine Pathway Metabolites and Cognitive Function in Major Depressive Disorder,” Psychoneuroendocrinology 101 (March 2019): 72–79.

J. C. Feiger et al. “Inflammation Is Associated with Decreased Functional Connectivity Within Corticostriatal Reward Circuitry in Depression,” Mol. Psychiatry 21, № 10 (October 2016): 1358–1365.

M. Visser et al. “Elevated C-Reactive Protein Levels in Overweight and Obese Adults,” JAMA 282, № 22 (December 1999): 2131–2135.

K. A. Walker et al. “Midlife Systemic Inflammatory Markers Are Associated with Late-Life Brain Volume: The ARIC Study,” Neurology 89, № 22 (November 2017): 2262–2270.

Технически гречиха и киноа – это псевдозлаки, а не зерна. Прим. авт.

Masashi Soga, Kevin J. Gaston, and Yuichi Yamaurac.“Gardening Is Beneficial for Health: A Meta-analysis,” Preventative Medicine Reports 5 (March 2017): 92–99.

Centers for Disease Control and Prevention, “Short Sleep Duration Among U.S. Adults”. https://www.cdc.gov/sleep/data_statistics.html.

Список литературы и сведения о сне можно найти на сайте Национального фонда сна по адресу SleepFoundation.org.

C. S. Möller-Levet et al. “Effects of Insufficient Sleep on Circadian Rhythmicity and Expression Amplitude of the Human Blood Transcriptome,” Proc. Natl. Acad. Sci. USA 110, № 12 (March 2013): E1132–41.

Matthew Walker. Why We Sleep: Unlocking the Power of Sleep and Dreams (New York: Scribner, 2017).

Уолкер М. Зачем мы спим. Новая наука о сне и сновидениях. – М.: КоЛибри, 2019. Прим. ред.

J. G. Jenkins and K. M. Dallenbach. “Obliviscence During Sleep and Waking,” Am. J. Psychol. 35, № 4 (October 1924): 605–612.

A. S. Lim et al. “Sleep Fragmentation and the Risk of Incident Alzheimer’s Disease and Cognitive Decline in Older Persons,” Sleep 36, № 7 (July 2013): 1027–1032.

L. K. Barger et al. “Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome,” J. Am. Heart Assoc. 6, № 10 (October 2017): e006959.

C. W. Kim et al. “Sleep Duration and Progression to Diabetes in People with Prediabetes Defined by HbA1c Concentration,” Diabet. Med. 34, № 11 (November 2017): 1591–1598.

M. R. Irwin, R. Olmstead, and J. E. Carroll. “Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation,” Biol. Psychiatry 80, № 1 (July 2016): 40.

T. B. Meier et al. “Relationship Between Neurotoxic Kynurenine Metabolites and Reductions in Right Medial Prefrontal Cortical Thickness in Major Depressive Disorder,” Brain Behav. Immun. 53 (March 2016): 39–48.

S. M. Greer, A. N. Goldstein, and M. P. Walker. “The Impact of Sleep Deprivation on Food Desire in the Human Brain,” Nat. Commun. 4 (2013): 2259.

M. P. St-Onge et al. “Short Sleep Duration Increases Energy Intakes but Does Not Change Energy Expenditure in Normal-Weight Individuals,” Am. J. Clin. Nutr. 94, № 2 (August 2011): 410–416.

J. S. Rihm et al. “Sleep Deprivation Selectively Upregulates an Amygdala – Hypothalamic Circuit Involved in Food Reward,” J. Neurosci. 39, № 5 (January 2019): 888–899.

C. A. Everson. “Functional Consequences of Sustained Sleep Deprivation in the Rat,” Behav. Brain. Res. 69, № № 1–2 (July-August 1995): 43–54.

J. J. Iliff et al. “A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β,” Sci. Transl. Med. 4, № 147 (August 2012): 147ra111.

L. Xie et al. “Sleep Drives Metabolite Clearance from the Adult Brain,” Science 342, № 6156 (October 2013): 373–377.

E. Shokri-Kojori et al. “β-Amyloid Accumulation in the Human Brain After One Night of Sleep Deprivation,” Proc. Natl. Acad. Sci. USA 115, № 17 (April 2018): 4483–4488.

P. Li et al. “Beta-Amyloid Deposition in Patients with Major Depressive Disorder with Differing Levels of Treatment Resistance: A Pilot Study,” EJNMMI Res. 7, № 1 (December 2017): 24; см. также S. Perin et al. “Amyloid Burden and Incident Depressive Symptoms in Preclinical Alzheimer’s Disease,” J. Affect. Disord. 229 (March 2018): 269–274.

E. Flores-Martinez and F. Peña-Ortega. “Amyloid β Peptide-Induced Changes in Prefrontal Cortex Activity and Its Response to Hippocampal Input,” Int. J. Pept. 12 (January 2017): 1–9.

B. T. Kress et al. “Impairment of Paravascular Clearance Pathways in the Aging Brain,” Ann. Neurol. 76, № 6 (December 2014): 845–861.

S. Yoo et al. “The Human Emotional Brain Without Sleep – A Prefrontal Amygdala Disconnect,” Curr. Biol. 17, № 20 (2007): 877–878.

Источник: Seung-Schik Yoo et al., Current Biology 17 (20): R877–8. October 2007.

E. van der Helm and M. P. Walker. “Overnight Therapy? The Role of Sleep in Emotional Brain Processing,” Psychol. Bull. 135, № 5 (September 2009): 731–748.

A. N. Goldstein and M. P. Walker. “The Role of Sleep in Emotional Brain Function,” Annu. Rev. Clin. Psychol. 10 (2014): 679–708.

Y. Motomura et al. “Two Days’ Sleep Debt Causes Mood Decline During Resting State via Diminished Amygdala-Prefrontal Connectivity,” Sleep 40, № 10 (October 2017).

E. Ben Simon and M. P. Walker. “Sleep Loss Causes Social Withdrawal and Loneliness,” Nat. Commun. 9, № 3146 (August 2018).

K. J. Brower and B. E. Perron. “Sleep Disturbance as a Universal Risk Factor for Relapse in Addictions to Psychoactive Substances,” Med. Hypotheses 74, № 5 (May 2010): 928–933.

Grand View Research. “Insomnia Therapeutics Market Analysis by Treatment Type [Devices, Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists)], by Sales Channel, and Segment Forecasts, 2018–2025,” October 2017. https://www.grandviewresearch.com/industry-analysis/insomnia-therapeutics-market.

Yinong Chong, Cheryl D. Fryar, and Quiping Gu. “Prescription Sleep Aid Use Among Adults: United States, 2005–2010,” Centers for Disease Control and Prevention, NCHS Data Brief 127, August 2013. https://www.cdc.gov/nchs/products/databriefs/db127.htm.

T. B. Huedo-Medina et al. “Effectiveness of Non-Benzodiazepine Hypnotics in Treatment of Adult Insomnia: Meta-Analysis of Data Submitted to the Food and Drug Administration,” BMJ 345 (December 2012): e8343.

D. F. Kripke, R. D. Langer, and L. E. Kline. “Hypnotics’ Association with Mortality or Cancer: A Matched Cohort Study,” BMJ Open 2 (2012): e000850.

D. F. Kripke. “Hypnotic Drug Risks of Mortality, Infection, Depression, and Cancer: But Lack of Benefit,” version 3, F1000Res. 5 (2016): 918.

Kripke. “Hypnotic Drug Risks.”

A. M. Chang et al. “Evening Use of Light-Emitting eReaders Negatively Affects Sleep, Circadian Timing, and Next-Morning Alertness,” Proc. Natl. Acad. Sci. USA 112, no. 4 (January 2015): 1232–1237.

J. M. Zeitzer et al. “Sensitivity of the Human Circadian Pacemaker to Nocturnal Light: Melatonin Phase Resetting and Suppression,” J. Physiol. 526, part 3 (August 2000): 695–702.

A. Garcia-Saenz et al. “Evaluating the Association Between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study),” Environ. Health Perspect. 126, № 4 (April 2018): 047011.